Inhibitory/repressor-receptors are upregulated significantly on activated T cells, and have been the molecules of attention as targets for inducing immune tolerance. Induction of effective antigen specific tolerance depends on concurrent engagement of the TCR and one or more of these inhibitory receptors. Here, we show, for the first time that dendritic cells (DCs) can be efficiently engineered to express multiple T cell inhibitory ligands, and enhanced engagement of T cell inhibitory receptors, upon antigen presentation, by these DCs can induce effective CD4+ T cell tolerance and suppress autoimmunity. Compared to control DCs, antigen presentation by DCs that ectopically express CTLA4, PD1 and BTLA selective ligands (B7.1wa, PD-L1, and HVEM-CRD1 respectively) individually (mono-ligand DCs) or in combination (multi-ligand DCs) causes an inhibition of CD4+ T cell proliferation and pro-inflammatory cytokine response, as well as increase in Foxp3+ Treg frequency and immune regulatory cytokine production.
Introduction
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), Programmed cell death-1 (PD1) and Band T-lymphocyte attenuator (BTLA) are the major inhibitory/repressor/negative-regulatory receptors expressed on T cells, upon T-cell activation in particular 1 . CTLA4 can not only downregulate T cell responses upon binding to B7.1 and B7.2 (shared ligands of CD28), its interaction with these ligands also curbs activating signals from APCs 2,3 . This receptor, through multiple mechanisms, plays a critical role in peripheral T cell tolerance, T cell homeostasis and regulatory T cell (Treg) function [4] [5] [6] [7] [8] [9] [10] [11] [12] . CTLA4 deficient mice undergo a massive lymphoproliferative condition and multi-organ autoimmunity 13, 14 suggesting that this receptor functions as a master regulator of peripheral tolerance mechanism(s). PD1 is a member of the CD28/CTLA4 family, and it is induced on peripheral T and B cells upon activation and its interaction with B7H1 (PD-L1) and B7DC (PD-L2) activates negative regulatory function 15, 16 . The ability of PD-L1 on T cells to act as a negative regulator, upon its interaction with B7.1 of APCs, has also been described 17 . PD1 deficiency leads to increased susceptibility to autoimmunity as well as spontaneous autoimmune features at older ages 18 , indicating its contribution to immune tolerance. Very low level of CTLA-4 and PD1 are sufficient for inhibition of the earliest stages of T cell activation through ligand-binding, and co-ligation of these receptors with TCR/CD28 is necessary for this inhibitory function 15, 19, 20 . Importantly, studies have shown that signaling through CTLA4 and PD1 contributes to the generation and/or functioning of natural and adaptive/induced Tregs 10, 21, 22 . BTLA, another CD28/CTLA-4 family member, is expressed on activated T and B cells, and its signals can also suppress T-cell response 23 . BTLA interacts with a TNFR family member, HVEM, a herpes virus entry mediator 24, 25 . Although HVEM is also known to interact with the T cell activation receptor LIGHT, it dominantly engages BTLA and CD160 on activated T cells through its CRD1 region, and negatively regulates T cell response 25, 26 . Although BTLA deficient mice fail to show spontaneous autoimmune features, they do exhibit an increased susceptibility to autoimmunity 23, 27 .
Above described aspects suggest that CTLA4, PD1 and BTLA can, individually or in combinations, be excellent targets for promoting peripheral immune tolerance, and the T cell negative regulatory properties of these receptors can be harnessed for autoimmune therapy. Importantly, inhibition of T cell response requires delivering active negative signals through these repressor receptors in conjunction with TCR engagement 19, [28] [29] [30] [31] . Therefore, induction of antigen specific tolerance by targeting CTLA4, PD1 and/or BTLA may require concomitant engagement of antigen specific TCRs and enhanced signaling through these receptors.
Previously, we have shown that dominant engagement of CTLA-4 on T cells from target tissues and antigen presenting dendritic cells (DCs) can induce Treg response, antigen specific T cell tolerance, and prevent and treat autoimmune experimental autoimmune thyroiditis (EAT) and spontaneous type 1 diabetes (T1D) in mouse models [32] [33] [34] [35] [36] . We have also shown that dominant engagement of CTLA-4 by its preferential ligand, B7.1 on DCs could lead to the induction of adaptive Tregs and suppression of T1D 34 . Previous reports have also shown that DCs that are depleted of co-stimulatory molecules induce tolerance 37, 38 , Nevertheless, exogenous expression of ligands in primary immune cells such as DCs for selectively enhancing T cell inhibitory receptor engagement, concurrent targeting of multiple receptors particularly, for generating tolerogenic antigen presenting cells (tAPCs) has not been reported before. Here, we tested if "potent" tAPCs can be generated by engineering the DCs to exogenously express selective ligands for CTLA4, PD1 and BTLA individually (mono-ligand DCs) or in combination (multiligand DCs) to harness the T cell inhibitory functions of these receptors and produce robust immune tolerance. We show that DCs can be efficiently engineered to simultaneously express multiple T cell repressor receptor-selective ligands using a lentiviral transduction approach, and antigen-loaded ligand-expressing engineered DCs, multi-ligand DCs in particular, can act as powerful tAPCs. These engineered DCs can induce profound inhibition of T cell proliferation, modulation of cytokine response, and generation of T cells with a regulatory phenotype, both in vitro and in vivo. Treatment of mouse model of experimental autoimmune thyroiditis (EAT) using mouse thyroglobulin (mTg)-loaded inhibitory ligand-DCs caused suppression of autoreactive T cell and antibody responses and amelioration of thyroiditis severity. Overall, this study, for the first time, demonstrates that engineering the DCs for expressing ligands specific for multiple T cell inhibitory receptors concomitantly is an effective way to produce tAPCs, and enhanced activation of multiple T cell repressor pathways by these cells can effectively suppress the ongoing autoimmunity.
Results:

T cell negative regulatory ligand expressing DCs modulate T cell response in vitro
Since negative regulatory pathways in T cells play a key role in peripheral immune tolerance, we hypothesized that overexpression of selective ligands for CTLA4, PD1 and BTLA receptors could make DCs produce tolerogenic effects on T cells through enhanced receptor engagement upon antigen presentation. To test this hypothesis, we engineered the bone marrow (BM) derived suggesting that lentiviral transduction alone could activate the DCs. On the other hand, LPS treated non-transduced and lentivirus transduced DCs produced more or less comparable levels of surface markers and cytokines. Further, compared to non-treated DCs, LPS-treated nontransduced and virus-transduced DCs induced comparable, although significantly higher than untreated DCs, degrees of T cell activation and cytokine production. Therefore, since effective initial activation of T cells is an important step in inducing Ag specificity to T cell tolerance and to minimize susceptibility to changes in their antigen presentation properties in vivo when injected, we used LPS exposed control and ligand expressing DCs for rest of the study.
To assess the functional ligand expression, B7.1wa, PD-L1 and HVEM-CRD1 lentivirus transduced DCs ( Fig. 2A) were examined for ligand levels and the soluble receptor binding abilities by FACS. Staining using ligand specific antibodies showed that virus transduced cells express profoundly higher levels of respective ligands compared to non-transduced cells ( Fig.   2B ). Further, incubation with soluble receptors followed by fluorochrome-labeled secondary antibody reagent demonstrated greater degree of binding by respective receptors in transduced cells compared to control cells, indicating that these exogenously expressed ligands are functional in terms of engaging the respective receptors. Of note, since WT B7.1 binds to both CTLA4 and CD28, and WT HVEM binds to BTLA and LIGHT, previously described CTLA4 and BTLA selective binding abilities of B7.1wa and HVEM-CRD1 39, 40 , were confirmed using 293T cells expressing these ligands (not shown).
To examine differences in the abilities of T cell negative regulatory ligand expressing DCs to activate T cells, control, B7.1wa, PD-L1 and HVEM-CRD1 DCs were pulsed with OT-II peptide and cultured with CD4+ T cells enriched from OT-II mouse spleen. As observed in Fig. 2C , T cells cultured with all three ligand DCs showed an overall lower rate of proliferation as compared to those cultured with control engineered DCs. Importantly, to determine if the suppression of T cell proliferation is due to enhanced receptor engagement, anti-CTLA4 antibody, PD1-Ig and BTLA-Ig were added to respective cultures to block receptor-ligand interaction. Supplemental Fig. 3 shows that blockade of receptor interaction with respective ligand in the culture reversed the suppressive effect on T cell proliferation induced by selective ligand expressing engineered DCs, supporting the notion that ligand DC induced effects are primarily due to enhanced T cell inhibitory receptor engagement.
To further assess the effect of enhanced T cell inhibitory receptor engagement upon antigen presentation, supernatants from primary cultures were examined for IL2 levels. CD4+ T cells activated using all three inhibitory ligand DCs produced significantly lower amounts of IL2 compared to control DC activated cells ( Fig. 2D ). Importantly, analysis of cytokines secreted by T cells from these primary cultures, upon antigen challenge, shows that antigen presentation by ligand DCs, B7.1wa-DCs and PD-L1-DCs particularly, induced IL10 producing T cells. Further, T cells activated using all three ligand DCs produced significantly lower amounts of IFNγ compared to control DC activated T cells. Overall, these observations suggest that enhancing the CTLA4, PD1 and BTLA selective ligand strength on antigen presenting DCs results in suppression of T cell responses, albeit different outcomes in-terms of the type of response when different receptors were targeted.
Multi-ligand DCs suppress T cell responses more effectively than mono-ligand DCs in vitro
Next, we examined if multiple T cell negative regulatory ligands can be efficiently expressed simultaneously on DCs and it provides the DCs with a better ability, as compared to expression of individual ligands, to suppress or modulate T cell response upon antigen presentation. To test this, multi-ligand DCs were generated using lentiviral vectors encoding different fluorescent-tag versions of T cell negative regulatory ligands (B7.1wa-CFP, PD-L1-YFP and HVEM-CRD1-RFP; shown in Supplemental Fig. 1B ), and the ligand expression levels and receptor binding abilities were confirmed microscopically and/or by FACS ( Fig. 3A and 3B ). The multi-ligand DCs were then, along with mono-ligand and control DCs, pulsed with OT-II peptide and used for antigen presentation assays in vitro. As observed in Fig. 3C and 3D, fluorescent-tag mono-ligand DCs induced proliferative and IL2 responses in OT-II CD4+ T cells, similar to the response induced by non-tagged ligand DCs (shown in Fig. 2 ). Importantly, the proliferative and IL2 responses of OT-II CD4+ T cells were significantly lower when multi-ligand DCs, compared to individual ligand or control DCs, were used for antigen presentation.
Of note, while the levels of early activation marker CD69 were relatively lower in individual and multi-ligand DC activated T cells compared to control DC activated cells at 16 h time-point, this difference was considerably increased by 48h time-point (Supplemental Fig. 4A ). Similarly, the differences in the degree of suppression of IL2 production by control and ligand DCs was more profound at 72 h, compared to 36h, time-point (Supplemental Fig. 4B ). These observations suggest that the early activation of T cells is suppressed less profoundly than later activation state by negative regulatory ligand expressing DCs, and the enhanced inhibitory receptor engagement occurs mainly after initial activation of T cells. It is important to note, as reported before 13, 17, 19, 23, 40 , that initial activation of T cells by antigen specific TCR engagement is critical for upregulating the expression of T cell inhibitory receptors.
Multi-ligand DCs modulate T cell function more effectively than mono-ligand DCs
To further realize the impact of enhanced engagement of repressor receptors by multi-ligand 
Multi-ligand DCs modulate T cell response more effectively than mono-ligand DCs in vivo
To examine the ability of T cell negative regulatory ligand-expressing DCs to modulate antigen specific T cell response in vivo, Ova primed C57BL/6 mice were treated with Ova-pulsed control and ligand DCs and examined for the T cell phenotype and proliferative response, and Ova specific antibody levels. As observed in in vitro assays (shown in Fig. 4 ), significantly higher frequencies of splenic CD4+ T cells from B7.1wa-DC and multi-ligand DC recipient mice were Foxp3+ compared to control DC recipient mice ( Fig. 5A ). Furthermore, CFSE dilution assay demonstrated that the abilities of CD4+ T cells from B7.1wa, PD-L1, HVEM-CRD1, and multi-ligand DC recipients to respond to Ova challenge were relatively lower compared to T cells from control DC recipients, with the T cells from multi-ligand DC recipients showing the least proliferation upon challenge with Ova ( Fig. 5B ). Cytokine response of T cells from ligand DC treated mice showed a trend similar to that observed in the in vitro assay of Fig. 4 (Fig. 5C ).
Importantly, better suppression of anti-Ova antibody response was achieved when the mice were injected with multi-ligand DCs compared to those that received mono-ligand DCs (Fig. 5D ).
Overall, these results suggest that while enhanced engagement of different repressor receptors by antigen presenting DCs modulates T cell function differently, they exert more effective regulation of T cell, and eventual B cell, responses upon co-engagement. One of the key common features of all ligand DCs, albeit the differences in magnitudes, appears to be the ability to induce IL10 production in T cells suggesting the contribution of this cytokine to hyporesponsiveness of T cells and to the overall immune tolerance. Hence, we determined the contribution of IL10 to immune modulation mediated by ligand-DC activated CD4+ T cells. As 
Treatment with T cell negative regulatory ligand expressing DCs during EAT induction results in suppression of autoimmunity and thyroiditis severity
To determine the ability of ligand DCs to modulate autoimmune response in vivo, mTg immunization model of EAT was employed. CBA/J mice were immunized with mTg on days 0 and 10, and cohorts of mice were treated during the disease induction stage with mTg pulsed control or multi-ligand DCs on days 5 and 15, and the degree of thyroiditis severity and the autoantibody response were determined on day 40. As shown in Fig. 6A , while treatment using mono-ligand DCs, compared to control DCs, resulted in significant suppression of thyroiditis severity, mice that received multi-ligand DCs showed profoundly lower thyroiditis severity.
Further, while treatment of EAT mice with mono-ligand DCs and multi-ligand DCs resulted in significantly lower mTg specific IgG1 and IgG2a (Fig. 6B ) autoantibody production compared to control DC treated mice, with the multi-ligand DC treated group showing the most profound suppression of autoantibody production. Draining cervical LN cells from cohorts of mice euthanized on day 30 were examined for proliferative and cytokine responses upon mTg challenge ex vivo. Ligand DC treated mice, compared to control DC recipients, showed significantly lower T cell proliferative response upon challenge with mTg (Supplemental Fig. 8 ), a trend similar to that of Ova primed mice described under Fig. 5 . Importantly, as observed in Ova primed mice as well as in the in vitro assays, both B7.1wa and multi-ligand DC treated mTg primed mice showed significantly higher frequencies of Foxp3+ CD4+ T cells compared to other groups ( Fig. 6C ). Interestingly, LN cells from all ligand DC recipient mice produced profoundly lower IFNγ and higher IL10 upon ex vivo challenge with mTg ( Fig. 6D ). On the other hand, while CD4+ T cells from B7.1wa DC treated mice produced higher amounts of IL17 compared to control DC recipients, IL17 response of T cells was lower when the mice were treated with PD-L1 DCs or multi-ligand DCs. These observations have been substantiated by detection of correlating frequencies of IFNγ+, IL17+ and IL10+ CD4 T cells upon intracellular staining of fresh splenic CD4+ from ligand DC treated mice (Supplemental fig 9) . Overall, these results show that T cell negative regulatory ligand expressing DCs, multi-ligand DCs particularly, have the potential to induce robust hyporesponsiveness against self-antigens and promote protection against autoimmune destruction of target organ.
Discussion
DCs are considered the most effective APCs and the only type of cells that are capable of activating naïve T cells 41, 42 . Hence, they can play an important role in breaking tolerance and in initiating autoimmune responses. These APCs are capable of capturing antigens from the site of inflammation and presenting it to T cells at lymphoid organs 43 . These properties make the DCs most efficient APCs, and indicate that they can be used to effectively induce T cell activation or tolerance if the immunological synapse is appropriately manipulated. While DCs maintained in an immature state are considered tolerogenic due to significantly low expression of costimulatory molecules and/or pro-inflammatory cytokines 44, 45 , these cells are highly susceptible to maturation in vivo, especially under pro-inflammatory microenvironment in autoimmune conditions, and can produce adverse effects during therapy. Hence, engineering the DCs to ensure the maintenance of their tolerogenic function, even under the pro-inflammatory conditions, is critical for autoimmune therapy. In this regard, DCs that are selectively deleted of costimulatory molecules or ectopically expressing cytokine and non-cytokine factors have shown the ability to induce T cell tolerance 37, 46, 47 . On the other hand, we reported that enhancing CTLA4 agonist strength on mature DC surface could lead to dominant engagement of repressorreceptor on T cells upon antigen presentation and induce antigen specific Tregs and T cell tolerance 35, 36 . This suggested to us that enhancing the strength of one or more T cell repressor receptor selective ligands by exogenous expression can be an effective strategy to generate efficient tolerogenic DCs and this approach will have immense potential in suppressing autoimmunity. However, exogenous or over-expression of multiple factors in DCs have been challenging due to the difficulty in transfecting these primary immune cells efficiently. This study, for the first time, demonstrates that lentiviral transduction system can be employed to generate tAPCs that are exogenously expressing ligands for multiple T cell repressor receptors.
While the functions of T cell inhibitory receptors such as CTLA4, PD1 and BTLA have been well studied and the impact of engaging these receptors for modulating T cell function has been recognized 1, 14, 17, 23 , our study describes a DC-based approach to hyper-activate these T cell inhibitory pathways individually or in combination during antigen presentation to induce robust T cell tolerance.
We predicted that engineering the DCs to ectopically / over express T cell inhibitory ligands will result in selective and enhanced engagement of negative regulatory-receptors on T cells, especially during antigen specific activation, and modulate the function of these T cells resulting in antigen specific immune tolerance. Since early activation of T cells results in increased expression of negative regulatory receptors such as CTLA4, PD-1 and BTLA 13, 17, 19, 23, 40 , enhanced engagement and active T cell repression can occur mainly in antigen experienced / TCR engaged T cells. Further, since the natural expression of T cell activation ligands such as CD80 and CD86 on these engineered DCs is not restricted due to ectopic expression of T cell inhibitory receptor selective ligands, they can activate T cells initially to provide antigen specificity and to upregulate repressor-receptor expression. It will then be followed by a strong suppression of these T cells mediated by enhanced-ligation induced active signaling through these receptors. Validating this notion, here we show that LPS-treated (mature) DCs that are ectopically expressing CTLA4, PD1 and BTLA selective ligands, primarily aimed at enhanced inhibitory receptor engagement upon antigen presentation, can effectively induce CD4+ T cell hyporesponsiveness both in vitro and in vivo. Moreover, we show that treatment with DCs that ectopically express selective ligands of all three receptors results not only in the modulation of both T and B cell responses in vivo, but also ameliorates disease severity in a self-antigen immunization induced autoimmune model.
Mature DCs such as those treated with LPS are potent APCs that express high levels of antigen presentation associated surface molecules such as MHC, CD80 and CD86 as well as various cytokines 44, 48 ; hence ideal for activating T cells in an antigen specific manner. Further, mature DCs, as compared to immature DCs, could be less susceptible to microenvironment induced proinflammatory changes and not expected to produce undesired outcomes. In addition, unlike endogenous proteins, microenvironment is not expected to profoundly influence the levels of ectopically expressed surface ligands. Therefore, CTLA4, PD1 and BTLA selective ligand DCs substantiates this notion. Of note, previous reports have shown that DCs that express higher levels of PD-L1 suppress Th1 response, but not Th17 response. This discrepancy is perhaps associated with the type, maturation status, and PD-L1 levels of the DCs. Importantly, although B7.1wa DCs induce higher IL17 response, profoundly suppressed autoantibody and thyroiditis severity in EAT mice treated with these DCs suggest that this, especially in association with robust Treg and IL10 responses, is not a pathogenic response. Furthermore, many previous studies including ours [55] [56] [57] [58] [59] have shown that Th17/IL17 response in association with increased Tregs promotes protection from the disease in other autoimmune models.
Although CTLA4, PD1 and BTLA have inhibitory/repressor functions in T cells as indicated by suppression of IL2 production and T cell proliferation 13, 17, 19, 23, 40 , signaling by these receptors can produce different immune outcomes. We and others have shown that CTLA4 engagement during antigen presentation can induce both TGFβ1 and IL10 expression in T cells and promote Foxp3+ and IL10+ Treg generation 32, [34] [35] [36] 60 . PD1 activation has been shown to result in increased IL10
and Foxp3 expressing T cells [61] [62] [63] [64] . BTLA activation also contributes to generation of IL10 expressing T cells 65, 66 . Reciprocally, activation of these signaling pathways often suppresses the production of pro-inflammatory cytokines. Importantly, as indicated by the diminished levels of antigen specific antibodies in treated mice, our observations show that T cell inhibitory ligand Overall, our observations show that powerful tAPCs can be generated by engineering the DCs to express selective ligands of T cell repressor receptors, and this could be an attractive and effective approach for antigen specific autoimmune therapy. Moreover, the ability of these engineered DCs, multi-ligand DCs particularly, to affect multiple aspects of immune function, viz: higher Treg frequencies and immune regulatory cytokine responses, and lower proinflammatory IFNγ responses as well as both IgG2a and IgG1 responses against autoantigen suggests that such tAPCs could have therapeutic value in both T cell mediated and antibody mediated autoimmune diseases. Challenges of employing DC based approaches for human autoimmune therapy include engineering the DCs ex vivo efficiently and consistently for therapy and maintaining the tolerogenic phenotype and function of DCs in vivo upon therapeutic injection. As stated above, efficient engineering of the DCs for constitutive overexpression of multiple T cell inhibitory ligands, as described in this study, makes them less susceptible to changes in the functional properties and produces undesired outcomes upon in vivo therapeutic delivery; hence highly desired for clinical translation for treating autoimmune diseases such as thyroiditis and type 1 diabetes where self-antigens are known. Induction of antigen specific T cell tolerance is the key feature of DC based tolerogenic approaches. Although this approach needs to be further evaluated in a spontaneous model of autoimmunity, based on the outcomes of this proof-of-principle study, we envision that DCs generated from the human peripheral blood monocytes can be engineered similarly to express human T cell inhibitory ligands, loaded with antigen(s) of interest, and these autologous DCs will be injected back to the patient to reliably suppress the autoimmunity. While suppression of autoimmunity in at-risk subjects at pre-clinical stages can effectively prevent the clinical onset of disease, treatment of subjects with established diseases could result in minimized autoimmunity associated disease complications. Importantly, although mono-ligand DCs alone could be effective in inducing T cell tolerance in humans, our pre-clinical observations suggest that engineered multi-ligand DC therapy will be more robust in suppressing autoimmunity and associated complications.
Materials and methods
Mice, antigens, antibodies and other reagents
C57BL6, CBA/J, IL10-/-and OT-II TCR-transgenic (TCR-Tg) mice (OT-II mice) were originally purchased from the Jackson laboratory (Bar Harbor, ME, USA). Foxp3-GFP-knockin (ki) 77 Supplemental Table 1 .
Cloning and lentivirus production
The third-generation replication-incompetent lentiviral cDNA cloning vector and packaging plasmids (Supplemental Fig. 1) were purchased from SBI and modified for this study. For cloning eCFP, eYFP and mRFP cDNA, pCDH1-copGFP vector was digested using NheI Infectious titers/transduction unit (TU) of the virus were determined by using fresh HEK293T cells before using for transduction of DCs.
Generation of BM derived DCs
DCs were generated in vitro from BM cells as described before [34] [35] [36] 
Phagocytic assay
Lentivirus (CFP control vector) transduced and non-transduced DCs were left untreated or exposed to LPS for 24 h, incubated with varying number of 1 μm yellow fluorescent latex beads (Polysciences Inc) for 2 h or 6 h, stained with CD11c specific Ab and analyzed by FACS.
In vitro antigen presentation assay
Ova-MHC class II peptide pulsed DCs (2 × 10 4 cells/well) were plated in triplicate in 96-well Ubottom tissue culture plates along with unlabeled or CFSE-labeled purified CD4+ cells from OT-II or OT-II-Foxp3-GFP mice (1 × 10 5 cells/well) in complete RPMI 1640 medium. Control antibody, anti-CTLA4 antibody, PD1-Ig, BTLA-Ig or anti-TGF-β1 antibody were added to some cultures. After 4 days of culture, cells were subjected to surface and/intracellular staining using fluorochrome labeled Abs and examined for CFSE dilution or cytokine production by FACS.
Cells were subjected to brief activation using PMA and ionomycin (4 hours) in the presence of Brefeldin A before staining to detect intracellular cytokines. In some assays, equal number of cells from primary cultures were seeded along with OT-II peptide, freshly isolated splenic DCs for 24 h and the spent media was tested for cytokine levels by ELISA or multiplex assays.
Ova and mTg priming, and treatment with engineered DCs
For inducing Ova specific immune response, six to eight week old C57/BL6 mice were injected in the presence of antigen (10 μg Ova or 25 μg mTg/ml) and bacterial LPS (1 μg/ml), washed, and injected i.v. (2 × 10 6 DCs/mouse) twice at a 10-day interval (on days 5 and 15). Ova primed mice were euthanized between 25 days post-priming to determine immune response. Ova specific T cell proliferative and cytokine responses were examined using spleen by ELISA or multiplex assay, and serum samples were tested for Ova specific Ab response by ELISA as described earlier 33, 35, 80 . Mice that received mTg for inducing EAT were euthanized between 30 days of priming for determining T cell response using spleen and cervical LN cells, or on day 40 for examining thyroiditis severity and serum autoantibody levels.
Detection of anti-Ova and mTg Abs
Serum levels of anti-Ova or anti-mTg-specific total IgG, IgG1 and/or IgG2a Abs were determined by ELISA. Ninety six-well plates were coated with 0. were added to the wells in triplicate and incubated for 1 h at RT. After washing, the plates were further incubated with HRP-labeled anti-mouse IgG, IgG1, or IgG2a for 1 h at RT. The enzyme reaction was developed using TMB/hydrogen peroxide substrate and the absorbance was measured at 450 nm. Highest dilution that showed OD value ≥ 0.05 above the background OD was considered the antibody titer of a given sample.
Evaluation of EAT
Thyroids along with trachea were removed and fixed in 4% formaldehyde, 5-μm paraffin sections were made, and subjected to H&E staining to examine lymphocyte infiltration. Cellular infiltration and thyroid follicular damage were scored as grades 0 -4 as described in our earlier reports 33, 35, 80 .
Statistical analysis
Mean, SD, and statistical significance (p-value) by paired or unpaired T cells were calculated This assay was repeated at least twice with similar trends. Thyroiditis severity (grade) p=0.0002 p=0.025 p=0.0014 p=0.025
